Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2771)	4/16/2010 12:08:50 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

CRTX is up for 5th day on a roll.<g> bigcharts.marketwatch.com The stock was up 4.04% and is still up 3.14% at present with volume of 53.3Ks already > its ADV CRTX has 4Qs of better revenues, but earnings have been lower in the last 3Qs and the comparison with the pending 1stQ is not expected to be good since last Yr. it earned $0.48 vs. $0.10 in 2008 and $0.48 is what the EE are for the whole current Yr.<g> However, for 2011 the EE are around $0.70 and since CRTX has negligible LTD,+CF and the insiders hold a good % of the stock, is better to keep CRTX in mind.<g> The ACTAY is $10.50 and a long term target around $12 doesn't seems unreasonable. The Sep2005 was $97.50 <g> bigcharts.marketwatch.com On the recent Wall Street Transcript Biotechnology & Pharmaceuticals Report, it mentions CRTX as a "sleeper stock that is immensely profitable".<g> Bernard

To: Jibacoa who wrote (2771)	6/17/2010 11:47:01 AM
From: Jibacoa	1 Recommendation Respond to of 3722

IMGN dipped below the support at the $8 level on June 9 and is now trying to test the resistance at $9 <g> The stock is still up 1.85% on moderate volume about 1/5 its ADV bigcharts.marketwatch.com IMGN presented data of its IMGN388 at the ASCO meeting. The data that was reported, Abstract #3058, was from the first clinical trial conducted with IMGN388. IMGN388 has demonstrated favorable tolerability at the dose levels evaluated to date, and higher doses are now starting to be evaluated. IMGN388 is in development for the treatment of solid tumors. It utilizes the TAP technology. which consists of IMGN’s DM4 agent attached to an av integrin-targeting antibody using IMGN's method of attachment. The antibody component serves to target IMGN388 to av integrin-expressing cells and the DM4 serves to kill these cells.<g> IMGN has continued to reported lower revenues and higher losses. The EL for 2010 is around $0.90 vs. $0.62 in 2009 The ACTAY is $12.58 But it seems better to wait for further developments and see if the stock can close above the $9 and $10 resistance levels.<g> bigcharts.marketwatch.com Bernard